Nicholas K Arger1, Melissa Ho2, Prescott G Woodruff2, Laura L Koth2. 1. University of California, San Francisco, Division of Pulmonary and Critical Care, 505 Parnassus Ave, San Francisco, CA, 94143, USA. Electronic address: nicholas.arger@ucsf.edu. 2. University of California, San Francisco, Division of Pulmonary and Critical Care, 505 Parnassus Ave, San Francisco, CA, 94143, USA.
Abstract
BACKGROUND: Sarcoidosis is a systemic granulomatous disease of unknown etiology that affects the lungs in 90% of patients, but has a wide range of disease manifestations and outcomes including chronic and progressive courses. Noninvasive biomarkers are needed to assess these outcomes and guide decisions for long term monitoring and treatment. Interferon-gamma (IFN-γ)-inducible chemotactic cytokines (chemokines), CXCL9, CXCL10 and CXCL11, show promise in this regard because they have been implicated in the pathogenesis of and reflect the burden of granulomatous inflammation. CXCL11 has been reported to have unique functional properties in modulating adaptive immunity in model systems so our goal was to examine serum levels of CXCL11 in relation to clinical outcomes in a heterogeneous cohort of sarcoidosis subjects. METHODS: CXCL19, CXCL10, and CXCL11 serum levels were measured in sarcoidosis and healthy subjects using ELISA assay. We determined relationships between CXCL11 and standard clinical inflammatory markers, expression of IFN-γ-related genes in whole blood, organ involvement, dyspnea scores, and measures of pulmonary function. RESULTS: In a cross-sectional analysis of 104 sarcoidosis subjects, serum CXCL11 was significantly elevated compared to 49 healthy controls (p < 0.001). CXCL11 was positively correlated with CXCL9 and CXCL10 (p < 0.001), sedimentation rate (p < 0.01), and mean expression of three IFN-γ-related genes in whole blood (GBP1, STAT1, and STAT2) (p < 0.001). CXCL11 was inversely correlated with FVC %predicted (%pred) and FEV1 %pred and higher levels were associated with higher patient-reported dyspnea scores. We found positive correlations between CXCL11 and number of organs involved. Using survival analyses, we found that CXCL11 levels were predictive of future pulmonary function test (PFT) decline (log rank <0.001 and HR of log10(CXCL11) = 5.1, 95% CI 1.2-21, p = 0.026). CONCLUSIONS: The pattern of expression of serum CXCL11 in sarcoidosis patients suggests that this blood measure could be helpful in identifying patients that need longer-term monitoring for progressive thoracic and extra-thoracic sarcoidosis.
BACKGROUND:Sarcoidosis is a systemic granulomatous disease of unknown etiology that affects the lungs in 90% of patients, but has a wide range of disease manifestations and outcomes including chronic and progressive courses. Noninvasive biomarkers are needed to assess these outcomes and guide decisions for long term monitoring and treatment. Interferon-gamma (IFN-γ)-inducible chemotactic cytokines (chemokines), CXCL9, CXCL10 and CXCL11, show promise in this regard because they have been implicated in the pathogenesis of and reflect the burden of granulomatous inflammation. CXCL11 has been reported to have unique functional properties in modulating adaptive immunity in model systems so our goal was to examine serum levels of CXCL11 in relation to clinical outcomes in a heterogeneous cohort of sarcoidosis subjects. METHODS: CXCL19, CXCL10, and CXCL11 serum levels were measured in sarcoidosis and healthy subjects using ELISA assay. We determined relationships between CXCL11 and standard clinical inflammatory markers, expression of IFN-γ-related genes in whole blood, organ involvement, dyspnea scores, and measures of pulmonary function. RESULTS: In a cross-sectional analysis of 104 sarcoidosis subjects, serum CXCL11 was significantly elevated compared to 49 healthy controls (p < 0.001). CXCL11 was positively correlated with CXCL9 and CXCL10 (p < 0.001), sedimentation rate (p < 0.01), and mean expression of three IFN-γ-related genes in whole blood (GBP1, STAT1, and STAT2) (p < 0.001). CXCL11 was inversely correlated with FVC %predicted (%pred) and FEV1 %pred and higher levels were associated with higher patient-reported dyspnea scores. We found positive correlations between CXCL11 and number of organs involved. Using survival analyses, we found that CXCL11 levels were predictive of future pulmonary function test (PFT) decline (log rank <0.001 and HR of log10(CXCL11) = 5.1, 95% CI 1.2-21, p = 0.026). CONCLUSIONS: The pattern of expression of serum CXCL11 in sarcoidosispatients suggests that this blood measure could be helpful in identifying patients that need longer-term monitoring for progressive thoracic and extra-thoracic sarcoidosis.
Authors: Katrien Van Raemdonck; Philippe E Van den Steen; Sandra Liekens; Jo Van Damme; Sofie Struyf Journal: Cytokine Growth Factor Rev Date: 2014-11-22 Impact factor: 7.638
Authors: Robert Su; Michael M Li; Nirav R Bhakta; Owen D Solberg; Eli P B Darnell; Joris Ramstein; Suresh Garudadri; Melissa Ho; Prescott G Woodruff; Laura L Koth Journal: Eur Respir J Date: 2014-08-19 Impact factor: 16.671
Authors: Yaniv Zohar; Gizi Wildbaum; Rostislav Novak; Andrew L Salzman; Marcus Thelen; Ronen Alon; Yiftah Barsheshet; Christopher L Karp; Nathan Karin Journal: J Clin Invest Date: 2014-04-08 Impact factor: 14.808
Authors: G W Hunninghake; U Costabel; M Ando; R Baughman; J F Cordier; R du Bois; A Eklund; M Kitaichi; J Lynch; G Rizzato; C Rose; O Selroos; G Semenzato; O P Sharma Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 1999-09 Impact factor: 0.670
Authors: E Kriegova; R Fillerova; T Tomankova; B Hutyrova; F Mrazek; T Tichy; V Kolek; R M du Bois; M Petrek Journal: Eur Respir J Date: 2011-05-03 Impact factor: 16.671
Authors: Jennifer M Burns; Bretton C Summers; Yu Wang; Anita Melikian; Rob Berahovich; Zhenhua Miao; Mark E T Penfold; Mary Jean Sunshine; Dan R Littman; Calvin J Kuo; Kevin Wei; Brian E McMaster; Kim Wright; Maureen C Howard; Thomas J Schall Journal: J Exp Med Date: 2006-08-28 Impact factor: 14.307
Authors: Robert Su; Michelle-Linh T Nguyen; Misha R Agarwal; Christopher Kirby; Christine P Nguyen; Joris Ramstein; Eli P Darnell; Antonio D Gomez; Melissa Ho; Prescott G Woodruff; Laura L Koth Journal: Respir Res Date: 2013-11-07
Authors: Nicholas K Arger; Melissa E Ho; Isabel E Allen; Bryan S Benn; Prescott G Woodruff; Laura L Koth Journal: Respir Med Date: 2019-11-20 Impact factor: 3.415
Authors: Nicholas K Arger; Siddharth Machiraju; Isabel E Allen; Prescott G Woodruff; Laura L Koth Journal: Front Immunol Date: 2020-07-22 Impact factor: 7.561
Authors: Hok Sreng Te; David M Perlman; Chetan Shenoy; Daniel J Steinberger; Rebecca J Cogswell; Henri Roukoz; Erik J Peterson; Lin Zhang; Tadashi L Allen; Maneesh Bhargava Journal: BMC Pulm Med Date: 2020-06-01 Impact factor: 3.317